Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Effects of Garlic Supplements on Opioids in Healthy Volunteers

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Danny Shen, Fred Hutchinson Cancer Research Center
ClinicalTrials.gov Identifier:
NCT00499460
First received: July 10, 2007
Last updated: April 5, 2017
Last verified: April 2017

July 10, 2007
April 5, 2017
November 2006
August 2008   (Final data collection date for primary outcome measure)
Oxycodone Oral Clearance [ Time Frame: Serial blood sampling over 24 hours after a 15-mg oral dose of oxycodone ]
Oxycodone oral clearance is computed by Dose/AUC, where AUC is the area under the plasma oxycodone concentration-time curve from time zero to infinity. Oral clearance is a measure of the rate at which oxycodone is cleared from the body via metabolism.
Not Provided
Complete list of historical versions of study NCT00499460 on ClinicalTrials.gov Archive Site
  • Cold Pressor Tolerance AUC [ Time Frame: Repeated testing for tolerance to Cold Pressor Test just before and at 45, 90, 150 and 300 min after a single 15-mg oral dose of oxycodone ]
    Cold Pressor Test measures response to experimentally induced pain, in this case by immersion of a subject's hand in icy-cold water. Tolerance is the duration of time a subject is able to keep his/her hand immersed in the cold water. A prolongation in tolerance time indicates analgesic response to oxycodone treatment. Cold Pressor Tolerance AUC is the area under the tolerance versus time curve over a 300-min period after a test dose of oxycodone. Because of non-normality in sample distribution, log transformed AUC estimates were analyzed by Generalized Linear Model.
  • Somatic Side Effects Total Score [ Time Frame: SSE scores at 150 min after a single 15-mg oral dose of oxycodone ]
    Subjects rated the bodily side effects they experienced at 90, 150 and 300 min after oxycodone administration on a 35-item Somatic Side Effects (SSE) questionnaire. Total score (i.e., average of the scores for all 35 items) ranges on a numerical scale from 0 (no somatic side effects) to a maximum of 4 (extreme somatic aide effects). Only the peak SSE scores at 150 min are reported herein.
  • Cognitive-Affective Side Effects Total Score [ Time Frame: CASE scores at 150 min after a single 15-mg oral dose of oxycodone ]
    Subjects rated the mental side effects they experienced at 90, 150 and 300 min after oxycodone administration on a 36-item Cognitive-Affective Side Effects (CASE) questionnaire. Total score (i.e., average of the scores for all 36 items) ranges on a numerical scale from 0 (no somatic side effects) to a maximum of 4 (extreme somatic aide effects). Only the peak CASE scores at 150 min are reported herein.
  • Oral Midazolam Test [ Time Frame: Serial blood sampling over 6 hours after a 5-mg oral test dose of midazolam ]
    Midazolam when given orally is a probe substrate for the in vivo intestinal and hepatic activity of CYP3A (Cytochrome P450 3A) enzymes. The phenotype index in this case is the area under the plasma midazolam concentration from time zero to 360 min after a 5-mg oral test dose. A decrease in oral midazolam AUC indicates enhanced activity of CYP3A enzymes, possibly as a result of enzyme induction.
  • Oral Digoxin Test [ Time Frame: Serial blood sampling over 4 hours after a 0.5-mg oral test dose of digoxin ]
    Digoxin when given orally is a probe substrate for the efflux activity of P-glycoprotein in the small intestine. The phenotype index in this case is the area under the plasma digoxin concentration from time zero to 240 min after a 0.5-mg oral test dose. A decrease in oral digoxin AUC indicates an enhanced activity of P-glycoprotein, possibly as a result of transporter upregulation.
Not Provided
Not Provided
Not Provided
 
Effects of Garlic Supplements on Opioids in Healthy Volunteers
Modulation of Opioid Effects by Garlic Supplements

RATIONALE: Garlic supplements may alter the pharmacokinetics of oxycodone, thereby affecting its effectiveness as an opioid analgesic for the relief of moderate or severe pain.

PURPOSE: This randomized phase 4 trial is studying how garlic supplements may change the pharmacokinetics of oxycodone and its analgesic and side effects in healthy volunteers.

OBJECTIVES:

  • To determine whether CYP3A (Cytochrome P450 3A) and/or P-glycoprotein mediated interactions exist between garlic supplements and oxycodone (a commonly used oral opioid analgesic) in healthy volunteers.

OUTLINE:

This is a single-blind, randomized, crossover study. Participants are randomized to 1 of 2 arms. Each arm entails two 30-day treatment periods, with a washout of at least 4 weeks in between.

  • Arm I: In Period 1, participants receive oral garlic powder twice daily on days 1-28 and oral oxycodone on day 28. In Period 2, participants receive oral placebo twice daily on days 1-28 and oral oxycodone on day 28.
  • Arm II: In Period 1, participants receive oral placebo twice daily on days 1-28 and oral oxycodone on days 28. In Period 2, participants receive oral garlic powder twice daily on days 1-28 and oral oxycodone on day 28.

In both periods of each arm, participants receive a combination of oral midazolam and oral digoxin for CYP3A and P-glycoprotein phenotyping on day 29. Blood samples are collected periodically and analyzed by liquid chromatography-mass spectrometry (LC-MS).

Blood and urine samples are collected after receiving oxycodone for pharmacokinetic characterization. Plasma concentrations of oxycodone and its metabolites are measured by LC-MS.

Response to experimentally induced pain by the Cold Pressor Test (CPT) is assessed at baseline and periodically after oxycodone treatment. Subjective ratings of opioid side effects are assessed by validated questionnaires for somatic side effects and cognitive function impairments.

Interventional
Phase 4
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Participant
Primary Purpose: Basic Science
Healthy, No Evidence of Disease
  • Dietary Supplement: garlic powder tablets
    Each Garlicin tablet has a claimed allicin content of 3,200 microgram per tablet
    Other Name: Nature's Way Garlicin
  • Drug: oxycodone
    Single administration of three 5-mg oxycodone tablets or a 15-mg dose
    Other Name: oxycodone hydrochoride, Roxicodone
  • Arm I
    Two 30-day treatment periods separated by a washout of at least 4 weeks. In Period 1, participants receive oral garlic powder tablet twice daily on days 1-30, oral oxycodone on day 28, and a combination of oral midazolam and digoxin on day 29. In Period 2, participants receive oral placebo twice daily on days 1-30, oral oxycodone on day 28, and a combination of oral midazolam and digoxin on day 29.
    Interventions:
    • Dietary Supplement: garlic powder tablets
    • Drug: oxycodone
  • Arm II
    Two 30-day treatment periods separated by a washout of at least 4 weeks. In Period 1, participants receive oral placebo twice daily on days 1-30, oral oxycodone on day 28, and a combination of oral midazolam and digoxin on day 29. In Period 2, participants receive oral garlic powder tablet twice daily on days 1-30, oral oxycodone on day 28, and a combination of oral midazolam and digoxin on day 29.
    Interventions:
    • Dietary Supplement: garlic powder tablets
    • Drug: oxycodone
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
15
August 2008
August 2008   (Final data collection date for primary outcome measure)

INCLUSION CRITERIA:

  • Healthy volunteer
  • Body mass index 20-32

EXCLUSION CRITERIA:

  • Not pregnant
  • No history of cardiopulmonary, liver, renal, endocrine, neurologic, or psychiatric disease
  • No anemia
  • No known adverse reactions to opioids, benzodiazepines, cardiac glycosides, or garlic supplements
  • No known allergy or hypersensitivity to sulfur-containing food or drugs
  • No significant gastrointestinal intolerance to lactose in dairy products
  • No recent history of alcohol or substance abuse
  • No history of or concurrent heavy daily consumption of allium vegetables (i.e., garlic, shallots, leeks, and chives)
  • No handicaps due to visual and hearing impairments
  • No resting heart rate < 50 beats per minutes
  • No abnormal cardiac rhythm by EKG
  • No unusually sensitive response or resistance to pain stimulation (Cold Pressor Test)
  • Must be right handed
  • No color blindness
  • No history of learning disabilities or dyslexia
  • Must be literate and proficient in English
  • Must be a nonsmoker
  • No concurrent medication except oral contraceptives
  • No concurrent grapefruit or grapefruit juice
  • No other concurrent over-the-counter herbal products or herbal tea
Sexes Eligible for Study: All
21 Years to 45 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00499460
2040.00
IR-6130 ( Other Identifier: FHCRC IRB )
CDR0000551927 ( Other Identifier: PDQ )
R21CA118334 ( US NIH Grant/Contract Award Number )
No
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
No
Not Provided
Danny Shen, Fred Hutchinson Cancer Research Center
Fred Hutchinson Cancer Research Center
National Cancer Institute (NCI)
Principal Investigator: Danny D Shen, PhD Fred Hutchinson Cancer Research Center
Fred Hutchinson Cancer Research Center
April 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP